Who are Fosfomycun-trometamol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ceftazidime-avibactam + Fosfomycin, Meropenem + Fosfomycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fosfomycun-trometamol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fosfomycun-trometamol — Competitive Intelligence Brief

Fosfomycun-trometamol (Fosfomycun-trometamol) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphonic acid antibiotic. Area: Infectious Disease.

phase 3 Phosphonic acid antibiotic MurA (UDP-N-acetylglucosamine enolpyruvyl transferase) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Fosfomycun-trometamol (Fosfomycun-trometamol) — University Hospital, Rouen. Fosfomycin trometamol is a broad-spectrum antibiotic that inhibits bacterial cell wall synthesis by blocking peptidoglycan cross-linking.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Fosfomycun-trometamol TARGET	Fosfomycun-trometamol	University Hospital, Rouen	phase 3	Phosphonic acid antibiotic	MurA (UDP-N-acetylglucosamine enolpyruvyl transferase)
Ceftazidime-avibactam + Fosfomycin	Ceftazidime-avibactam + Fosfomycin	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor combination + phosphonic acid antibiotic	Penicillin-binding proteins (PBPs), beta-lactamases, MurA enzyme
Meropenem + Fosfomycin	Meropenem + Fosfomycin	National University of Singapore	marketed	Combination antibiotic (carbapenem + phosphonic acid antibiotic)	Penicillin-binding proteins (meropenem); MurA/UDP-N-acetylglucosamine enolpyruvyl transferase (fosfomycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphonic acid antibiotic class)

University Hospital, Rouen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fosfomycun-trometamol — Competitive Intelligence Brief. https://druglandscape.com/ci/fosfomycun-trometamol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab